IL10 and ovarian carcinoma: Treating murine and human myeloid DCs with exogenous IL-10 increases PD-1 expression and amplifies production of IL-10, leading to suppressed T and B cell responses and acquisition of resistance to anti-PD-1 therapy by ovarian cancer cells[117].